Fundraising Fox

Forwardvue Pharma

Mobile, US · Founded 2020 · Alabama corporation · 1 known investors

forwardvuepharma.com ↗

ForwardVue Pharma develops a long-acting ORAI1 blocker administered by intravitreal injection to treat retinal neovascular disease, with a target dosing of 1-2 injections per year for durability up to 12 months. The company operates in ophthalmic drug development.

BiotechHealthtechMedical Devices

Founders & leadership

Forwardvue Pharma was founded in 2020 by Alan Franklin.

AF
Alan FranklinOphthalmologist, Vitreoretinal Diseases and Surgery
RM
RAJ MATURINamed on SEC filing
AF
ALAN FRANKLINNamed on SEC filing
ND
NEIL DONNENFELDNamed on SEC filing
RT
RUBEN TIMMONSNamed on SEC filing
BB
BARRY BUTLERNamed on SEC filing
AS
AMIR SHOJAEINamed on SEC filing

Investors · 1

OphthaFundCharlestonvia Tom Mather · inferred

Reported raises · per SEC filings

Form D private placements
▶$1MofferedNov 2022 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • NEIL DONNENFELDDirector
  • ALAN FRANKLINExecutive Officer, Director
  • AMIR SHOJAEIDirector
  • RAJ MATURIDirector
  • RUBEN TIMMONSDirector
  • BOB KATZExecutive Officer, Director
  • BARRY BUTLERDirector
Offering amount
$1M
Minimum investment
$10K
Incorporated
Corporation, Alabama, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MofferedOct 2020 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • RAJ MATURIDirector
  • ALAN FRANKLINExecutive Officer, Director
  • NEIL DONNENFELDDirector
  • RUBEN TIMMONSDirector
  • BARRY BUTLERDirector
  • AMIR SHOJAEIDirector
Offering amount
$4M
Minimum investment
$10K
Proceeds to insiders
$50K
Incorporated
Corporation, Alabama, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Forwardvue Pharma do?
ForwardVue Pharma develops a long-acting ORAI1 blocker administered by intravitreal injection to treat retinal neovascular disease, with a target dosing of 1-2 injections per year for durability up to 12 months. The company operates in ophthalmic drug development.
Who founded Forwardvue Pharma?
Forwardvue Pharma was founded by Alan Franklin in 2020.
Who are Forwardvue Pharma's investors?
Forwardvue Pharma's investors include OphthaFund.
Where is Forwardvue Pharma headquartered?
Forwardvue Pharma is headquartered in Mobile, US.